The global contrast media injectors market size was valued at USD 1 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 4.83% from 2022 to 2030. The growth of the contrast media injectors market is attributed to the rising prevalence of chronic disorders, technological advancements, along with globally increasing demand for minimally invasive surgical procedures. The COVID-19 outbreak had a negative impact on the contrast media injectors market. Many radiology departments saw a rapid drop in imaging case volume during the COVID-19 pandemic, resulting in a slump in demand for contrast media injectors.
According to an article released by the Radiology Society of North America in April 2020, the pandemic will have a significant influence on radiology practices across the country. Moreover, according to an article published in the RSNA Journal in 2020 by Joseph J. Cavallo, radiology offices could expect a 50.0%–70.0% reduction in imaging volume for a minimum of 3–4 months, depending on the location of the practice and the severity of the COVID-19 outbreak in each area.
However, most countries throughout the world have begun to reduce security regulations and resume certain elective treatments, indicating that the market will continue to develop during the projection period. Additionally, organizations are gaining knowledge in their end-to-end supply chains to reduce product prices and improve the quality and services associated with contrast media injectors. Such operational ideas help organizations save money by eliminating third-party expenses. These characteristics are projected to generate lucrative market growth prospects.
The number of diagnostic imaging tests such as X-rays, ultrasounds, and advanced imaging equipment such as CT scans, MRIs, and others has augmented as the prevalence of long-term diseases and complex co-morbidities has increased. The ability of these tests to detect the need for the treatment/surgery in interventional procedures and perioperative imaging before surgeries would increase the number of contrast media procedures. Globally, chronic diseases are the primary cause of death, and a large number of people are affected by complicated morbidities which are expected to spur the market growth.
In addition, according to a report by CDC, the incidence of heart failure is increasing in the U.S., and it is one of the leading causes of death in the country. In 2020, approximately 659,000 people died due to cardiovascular diseases in the U.S. Moreover, by 2030, the number of people with heart diseases is estimated to increase by 46.0%. In most cases, deaths due to these diseases can be avoided if diagnosed at an early stage. Hence, the increasing prevalence of long-term diseases and complex co-morbidities are the major drivers as it is leading to the growth in demand for contrast media injectors.
Rapid technological advancements, a rise in healthcare expenditure, along with improvement in the quality of patient care are some of the major factors contributing to the global boost in demand for minimally invasive surgeries. Contrast media injectors can assist surgeons in accurately inserting a contrast agent to reduce human errors and increase the accuracy & efficiency of the surgical procedure. Contrast media injectors play a crucial role in intraoperative interventional radiology and interventional cardiology. The availability of advanced injector systems for diagnosis and intraoperative imaging is likely to propel their adoption.
In addition, key advantages offered by minimally invasive surgeries include speedy recovery, smaller incisions, low risk of infections, reduced scarring, minimal loss of blood during the procedure, and shorter hospital stays. These benefits are anticipated to boost the market during the forecast period. Additionally, minimally invasive procedures conducted with contrast media injectors provide real-time imaging and high quality, for surgical or diagnostic procedures, which can create significant opportunities for the surgeons to perform the surgical procedures in the appropriate area, augmenting the overall market.
Additionally, a growing number of approvals for contrast media injectors by regulatory bodies, such as the U.S. FDA and the EU, is predicted to actively contribute to the market growth. Leading manufacturers are making major investments in the development of high-end systems to cater to the unmet needs of their customers. These companies launch advanced systems, which can provide high accuracy, efficiency, and reliability to healthcare professionals.
For instance, in November 2020, GE Healthcare received the U.S. FDA’s approval for MRI contrast agent Claris can in prefilled syringes. This approval assisted the company to widen its product portfolio. Moreover, in December 2019, Bayer received the U.S. FDA’s approval for expanded use of MEDRAD Stellant Flex CT injection system in contrast-enhanced mammography. This approval helped the company improve its product offerings in breast imaging, which is expected to boost the market growth.
The U.S. dominated the market with the highest revenue share of 83.60% in 2021. An increase in the prevalence of several chronic diseases, including cardiac, neurological, and orthopedic disorders, is projected to propel the market. According to the Centers for Disease Control and Prevention, in 2020, approximately 5.8 million individuals in the U.S. were suffering from Alzheimer’s disease, and this number is estimated to reach nearly 14.0 million by 2060. Contrast media injectors provide high accuracy, precision, and better outcomes during surgical procedures. Thus, the growing prevalence of chronic diseases is expected to boost the number of surgical procedures, which is anticipated to propel the demand for contrast media injectors in the U.S.
The injector systems led the market and accounted for more than 61.33% share of the global revenue in 2021. Contrast agents are delivered into the bloodstream of patients during CT, MRI, and angiogram imaging procedures, allowing for improved visualization of the contrast of fluids or structures within the body. CT injector systems, MRI injector systems, and cardiovascular/angiography injector systems are all examples of contrast media injector systems. Among all, the CT injector systems segment accounts for the greatest proportion of the contrast media injectors market.
This is due to its widespread use in the detection and treatment of vascular disease, cancer, and orthopedic injuries and disorders. Moreover, technological advancements and the launch of new products are expected to propel the growth of the segment. For instance, in September 2019, The MedradStellant Flex CT injectable system from Bayer was released. The Stellant Flex system is a user-driven system with little technician training and automation. It provides personalized patient protocols and personalized imaging, as well as flexible capital equipment alternatives through the company's TechCare service.
The consumables segment is expected to register the highest CAGR of 5.73% during the forecast period. The augmented need for the consumables to ensure safety and hygienic conditions during diagnostic procedures can be linked to this segment's high growth rate. Additionally, it is expected that recurring purchases of these consumables for radiology, interventional cardiology, and interventional radiology will boost the segment's share. Furthermore, higher adoption of contrast media injector consumables, greater availability, and the increasing prevalence of chronic disorders worldwide are expected to spur the segment growth.
The single head injectors led the market and accounted for more than 44.44% share of the global revenue in 2021. Single head injectors are the most widely used injectors for angiography, CT, and MRI. These injectors involve the use of only one syringe for the delivery of contrast media. Single head injectors are used in angiography, while dual head injectors, equipped with two syringes, are mostly used in CT systems. Additionally, large application and low average selling price, single head injectors are the first choice of customers in emerging economies such as China, India, and Brazil due to budget constraints which is anticipated to spur the segment growth.
The syringe-less injectors segment is expected to exhibit the highest CAGR of 6.03% during the forecast period. Syringe-less power injectors have recently become popular as a way to cut down on contrast media waste. When considering the decreased cost and increased performance of the devices, the syringe-less injector provided a cost savings of roughly $8 per patient which is expected to drive the segment growth. Several major manufacturers are concentrating their efforts on the introduction and development of syringe-less injectors, which are expected to boost the market.
For instance, in November 2016, ulrichGmbH & Co. KG launched Max 2M and Max 3, innovative syringe-less MRI contrast media injector systems, which allow direct injection of contrast media from media containers without using a syringe, thereby providing more flexibility and saving time.
Radiology led the market and accounted for more than 47.39% share of the global revenue in 2021. Radiology involves the use of noninvasive imaging technologies such as CT and MRI scans to create highly comprehensive images. CT scanning involves the use of X-ray equipment to build a structure of cross-sectional pictures of the body to detect the source of a medical condition, especially in soft tissues whereas MRI technology involves the application of a magnetic field to create images inside of a patient’s body.
Contrast media injectors are used with CT and MRI to identify a broad range of health conditions such as breast cancer heart diseases, gastrointestinal conditions, broken bones, colon cancer, and blood clots. In addition, this segment is projected to grow at a lucrative rate owing to the non-invasive nature of radiology techniques and the rise in the prevalence of chronic diseases.
The interventional cardiology segment is anticipated to witness the fastest CAGR of 5.79% in the forecast period. The rising prevalence of cardiac conditions such as stroke, heart attack, arrhythmia, and heart valve disorders is expected to drive segment growth. As the prevalence of cardiovascular disorders rises, so does the demand for interventional cardiac surgery for treatment and diagnosis. Additionally, increasing technological advancements along with the number of hospital admissions will further drive the segment growth.
The hospital segment dominated the market and accounted for over 68.07% share of the global revenue in 2021, owing to increasing admissions of patients suffering from neurological disorders, cardiovascular diseases, and cancer. Hospitals are primary users of contrast media injectors, owing to their wide range of applications in radiology, interventional radiology, and interventional cardiology. Additionally, increasing focus on the development of healthcare infrastructure in developing economies of the Asia Pacific and Africa is expected to propel the segment growth.
The diagnostics centers are the second leading segment after hospitals accounted for more than 22.08% shares of the global revenue in 2021. The rise in the number of private imaging centers (driven by the increased demand for diagnostic imaging and early diagnosis) and the shortage of imaging modalities in small and mid-scale hospitals are two significant reasons driving the growth of diagnostic imaging centers. The demand for angiography operations, which are utilized for diagnosis, treatment planning, and prevention of chronic illnesses, is expected to rise as people become more aware of these conditions.
North America dominated the market and accounted for over 38.75% share of global revenue in 2021. The presence of well-established healthcare facilities and easy availability of advanced technologies as well as high demand for diagnostic procedures in this region is expected to increase the number of inpatient examinations which is expected to boost the market growth. Additionally, countries such as the U.S. and Canada have seen an increase in hospital admissions in recent years, as a result of the high occurrence of chronic medical diseases & fatal injuries. Chronic disease, for instance, is the leading cause of disability and mortality, according to CDC. In the U.S., four out of ten adults have two or more chronic diseases, and six out of ten adults have a chronic disease. In addition, the Canadian Institute of Health (CIH) reported that over 17,655 persons were hospitalized in 2016 and 2017 owing to sports-related injuries.
Asia Pacific contrast media injectors market is likely to grow at a 5.41% rate. Japan, China, and India are the major contributors to Asia Pacific’s contrast media injectors market. Rapidly developing economies, growing awareness about healthcare, and an aging population are among the key factors boosting the market in this region. The growing prevalence of chronic diseases, such as neurological disorders, and the increasing geriatric population are the factors expected to boost the demand for contrast media injectors. Moreover, neurological diseases are strongly associated with aging and mostly begin in people aged 60 years and older. Thus, there is a high demand for advanced surgical treatment solutions for these diseases, which is expected to propel the demand for advanced contrast media injectors.
The key players provide a broad range of advanced devices through their strong distribution and supply channels worldwide. In addition, leading players are involved in mergers & acquisitions, new product launches, strategic collaborations, and regional expansions to gain the maximum revenue share in the sector. Mergers & acquisitions help companies to expand their businesses and regional presence.
For instance, In December 2021, Guerbet and Bracco Imaging announced the signing of a global agreement for Gadopiclenol, a next-generation MRI contrast agent. In addition, in December 2021, to address the needs of hospitals and imaging networks, Qaelum NV has established a strategic agreement with Ulrich GmbH & Co. KG in Ulm to combine their sophisticated Contrast Management technology with Ulrich medical's contrast media injectors. Some prominent players in the global contrast media injectors market include:
Bayer HealthCare LLC
Bracco Group
Ulrich Medical
Guerbet Group
Medtron AG
Nemoto Kyorindo Co., Ltd.
Hong Kong Medi Co Limited
Report Attribute |
Details |
Market size value in 2022 |
USD 1.1 billion |
Revenue forecast in 2030 |
USD 1.65 billion |
Growth Rate |
CAGR of 4.83% from 2022 to 2030 |
Base year for estimation |
2021 |
Historical data |
2017 - 2020 |
Forecast period |
2022 - 2030 |
Quantitative units |
Revenue in USD million and CAGR from 2022 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, trends |
Segments covered |
Product, type, application, end use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; UK; Germany; France; Italy; Spain; Japan; China; India; Australia; South Korea; Brazil; Mexico; Colombia; Argentina; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Bayer Ag; Bracco Imaging S.p.A.; Ulrich medical; Guerbet; MEDTRON AG; Nemoto Kyorindo Co.; Ltd.Hong Kong Medi Co Limited |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the global Contrast Media Injectors Market report based on the product, type, application, end use, and region:
Product Outlook (Revenue USD Million, 2017 - 2030)
Injector Systems
CT injector systems
MRI injector systems
Cardiovascular/angiography injector systems
Consumables
Tubing
Syringe
Others
Type Outlook (Revenue USD Million, 2017 - 2030)
Single Head Injectors
Dual-Head Injectors
Syringe less Injectors
Application Outlook (Revenue USD Million, 2017 - 2030)
Radiology
Interventional Cardiology
Interventional Radiology
End Use Outlook (Revenue USD Million, 2017 - 2030)
Hospitals
Diagnostics Centers
Ambulatory Surgery Centers
Regional Outlook (Revenue, USD Million, 2017 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Asia Pacific
Japan
China
India
Australia
South Korea
Latin America
Brazil
Mexico
Argentina
Colombia
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
b. The global contrast media injectors market size was estimated at USD 1 billion in 2021 and is expected to reach USD 1.1 billion in 2022.
b. The global contrast media injectors market is expected to grow at a compound annual growth rate of 4.83% from 2022 to 2030 to reach USD 1.65 billion by 2030.
b. CT injector systems dominated the contrast media injectors market with a share of 53.44% in 2021. This is attributable to the rising widespread application of these systems in cancer surgery, neurosurgery, cardiovascular surgery, and spinal procedures.
b. Some key players operating in the contrast media injectors market include Bracco Group; Guerbet Group; Medtron AG; Bayer HealthCare LLC; Ulrich GmbH & Co. KG; Nemoto Kyorindo Co., Ltd.; GE Healthcare; VIVID IMAGING; Sino Medical-Device Technology Co., Ltd.; and APOLLO RT Co. Ltd.
b. Key factors that are driving the contrast media injectors market growth include technological advancements and increasing demand for minimally invasive surgeries.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
With COVID-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for COVID-19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.